LIFE bioCEEd has been featured in a new article published by Seznam Zprávy, highlighting our mission to bridge the gap between groundbreaking academic research and real-world impact.

Over the past year, we have screened hundreds of early-stage biotechnology projects across Europe and selected six promising innovations with the potential to transform the future of medicine. These include AI-powered respiratory diagnostics, novel therapies for multiple sclerosis and fibrosis, and breakthrough approaches for rare diseases.

As our founder Michal Zahradníček explains in the interview, Europe does not lack scientific excellence. What is often missing is the right capital, know-how, and commercial focus required to turn discoveries into products that can reach patients.

By investing at the earliest stages of development, Life bioCEEd aims to fill this critical gap and help unlock the full potential of academic research.

The article also discusses the challenges of technology transfer in Central Europe, the importance of supporting research before spin-offs are created, and LIFE bioCEEd's growing focus on identifying breakthrough science across the UK, Switzerland, and other leading innovation ecosystems.

Read the full interview with Michal Zahradníček in Seznam Zprávy: https://www.seznamzpravy.cz/clanek/ekonomika-firmy-je-tezke-zjistit-co-cesti-vyzkumnici-delaji-rika-investor-308448